GlaxoSmithKline has launched Hiberix (Haemophilus b Conjugate Vaccine [Tetanus Toxoid Conjugate]) for active immunization as a booster dose for the prevention of invasive disease caused by Haemophilus influenzae type b (Hib). Hiberix is indicated for use in children 15 months through 4 years of age (prior to fifth birthday) who have received a primary series with a Haemophilus b Conjugate Vaccine that is licensed for primary immunization.
With the availability of Hiberix, the increased supply of Hib vaccines will be sufficient to support a provider-initiated notification process to contact all children whose Hib booster dose had been deferred during the supply shortage of Hib vaccines in the U.S. In response, the CDC’s Advisory Committee on Immunization Practices (ACIP) has provided updated recommendations for Hib booster vaccination. The recommendations may be found at www.cdc.gov/mmwr/preview/mmwrhtml/mm5836a5.htm.
For more information call (888) 825-5249 or visit www.hiberix.com.